| 1 |
31989250 | Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine. | 2020 Mar |
1 |
| 2 |
22248274 | Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia. | 2012 |
1 |
| 3 |
22399596 | Antiproliferative and antitumor effects of azacitidine against the human myelodysplastic syndrome cell line SKM-1. | 2012 Mar |
2 |
| 4 |
21253674 | The anti-leukemic effect and molecular mechanisms of novel hydroxamate and benzamide histone deacetylase inhibitors with 5-aza-cytidine. | 2011 May |
1 |
| 5 |
21674861 | Expression analysis of genes involved in epigenetic regulation and apoptosis in human malignant haematopoietic cell lines treated with 5-azacytidine. | 2011 Jan-Mar |
1 |
| 6 |
21114827 | Reactivating aberrantly hypermethylated p15 gene in leukemic T cells by a phenylhexyl isothiocyanate mediated inter-active mechanism on DNA and chromatin. | 2010 Nov 29 |
1 |
| 7 |
19148494 | The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expression. | 2009 Feb |
1 |
| 8 |
17611569 | CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. | 2007 Sep |
2 |